Andrew Hollman Meyer - 02 Jan 2026 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Business Officer
Signature
/s/ James Pennington, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
02 Jan 2026
Net transactions value
-$25,799
Form type
4
Filing time
02 Jan 2026, 21:00:17 UTC
Previous filing
03 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Meyer Andrew Hollman Chief Business Officer C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO /s/ James Pennington, Attorney-in-Fact 02 Jan 2026 0001864159

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Sale $25,799 -1,879 -2.2% $13.73 83,095 02 Jan 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.